Vasomune Therapeutics completed enrollment in its Phase 2a trial of pegevongitide (AV-001) for patients hospitalized with pneumonia requiring supplemental oxygen. The randomized, double-blind, placebo-controlled study (AV001-004, NCT05123755) is Fast Track-designated by the FDA for prevention and treatment of moderate-to-severe ARDS associated with respiratory infection. With enrollment done, Vasomune said teams will proceed with data quality assurance, clinical-data review, site closeout, and database lock—steps expected to position the program for subsequent analysis. The therapy is designed to activate the Tie2 receptor and reinforce endothelial barrier function. The milestone keeps the program on track for a data readout cycle that could inform whether vascular-leak targeting translates into measurable clinical endpoints in serious respiratory illness.